First-in-Human Study of Naporafenib (LXH254) With or Without Spartalizumab in Adult Patients With Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations

We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.

Source: European Journal of Cancer - November 20, 2023 Category: Cancer & Oncology Authors: Filip Janku, Tae Min Kim, Gopakumar Iyer, Anna Spreafico, Elena Elez, Maja de Jonge, Noboru Yamamoto, Anthonie J. van der Wekken, Paolo Antonio Ascierto, Michela Maur, Frederik Marm é, Jean-Jacques Kiladjian, Sumit Basu, Fabienne Baffert, Amparo Buigues, Tags: Original Research Source Type: research